# Study to Examine the Effects of Oral Fenretinide

> **NCT06528457** · PHASE2 · COMPLETED · sponsor: **Island Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Dengue

## Interventions

- **DRUG:** ISLA101
- **DRUG:** Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06528457
- **Lead sponsor:** Island Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-05
- **Primary completion:** 2025-05-21
- **Final completion:** 2025-07-21
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06528457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06528457, "Study to Examine the Effects of Oral Fenretinide". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06528457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*